Recombinant factor VIIa in preterm neonates with prolonged prothrombin time.

Area of Science:

• Neonatal Medicine
• Hematology
• Pharmacology

Background:

• Premature infants often exhibit prolonged prothrombin times, increasing bleeding risks.
• Fresh frozen plasma is a standard treatment, but recombinant factor VIIa (rFVIIa) offers a targeted approach.

Purpose of the Study:

• To assess the efficacy of low and standard doses of rFVIIa in normalizing prothrombin time in preterm neonates.
• To compare the effects of rFVIIa with fresh frozen plasma administration.

Main Methods:

• A study involving preterm infants (<33 weeks gestation) with elevated prothrombin times (>48s).
• Administration of 5 µg/kg rFVIIa to five infants, followed by a comparison of 80 µg/kg rFVIIa versus 10 mL/kg fresh frozen plasma in other infants.
• Prothrombin time measurements were taken at baseline and at 1, 3, 6, and 12 hours post-treatment.

Main Results:

• A minimal dose of 5 µg/kg rFVIIa significantly reduced prothrombin time within one hour.
• A higher dose of 80 µg/kg rFVIIa demonstrated a more rapid and significant reduction in prothrombin time compared to fresh frozen plasma at 1 and 3 hours.
• No adverse side effects were observed, though two infants experienced bleeding events despite treatment.

Conclusions:

• Recombinant factor VIIa (rFVIIa) shows promise in partially normalizing prothrombin time in preterm neonates.
• rFVIIa may be a viable alternative to fresh frozen plasma for managing coagulopathy in this population.
• Further randomized controlled trials are necessary to confirm the hemostatic efficacy and safety of rFVIIa.